NASDAQ
02.09.25 | 22:00
1,720 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.08. | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 84 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 18.06. | Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung | 3 | Investing.com Deutsch | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 69 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.04 | 1 | Seeking Alpha | ||
| 14.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 131 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 28.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 134 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 27.03. | Stifel maintains Buy on Zentalis stock with $9 target | 2 | Investing.com | ||
| 27.03. | H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy | 1 | Investing.com | ||
| 26.03. | Zentalis Pharmaceuticals GAAP EPS of -$2.33 beats by $0.13, revenue of $67.43M beats by $26.81M | 3 | Seeking Alpha | ||
| 26.03. | Zentalis Pharmaceuticals files $250M mixed securities shelf | 1 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,584 | -0,22 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| MODERNA | 20,800 | +0,02 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
| VALNEVA | 3,632 | +2,89 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| NOVAVAX | 6,506 | +0,23 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| NUREXONE BIOLOGIC | 0,526 | +2,73 % | STRONG BUY - jetzt die massive Rallye? | ||
| CARDIFF ONCOLOGY | 1,674 | +0,12 % | Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IMMUNITYBIO | 2,015 | -1,23 % | ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform | ||
| ALDEYRA | 4,968 | +0,40 % | EMA grants orphan designation to Aldeyra's ADX-2191 for vitreoretinal lymphoma | ||
| IOVANCE BIOTHERAPEUTICS | 1,866 | -1,03 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
| COHERUS ONCOLOGY | 0,970 | -5,50 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,730 | -1,60 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| GUARDANT HEALTH | 57,12 | 0,00 % | Guardant Health, Inc.: Guardant Health und James Van Der Beek schließen sich zusammen, um das Bewusstsein für neue Fortschritte bei der Darmkrebsvorsorge für Erwachsene ab 45 Jahren zu schärfen | 75 der Patienten, die an Darmkrebs sterben, wurden nicht untersucht, oft weil die herkömmlichen Optionen als unangenehm oder unbequem empfunden werden Das von der FDA zugelassene Shield-Produkt... ► Artikel lesen | |
| ESPERION | 1,953 | -1,81 % | Esperion Therapeutics, Inc.: Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias | ||
| VOYAGER THERAPEUTICS | 3,114 | +1,10 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| MACROGENICS | 1,600 | +7,31 % | MacroGenics, Inc.: MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities | Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement... ► Artikel lesen |
ZENTALIS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,720 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.